Potential Risks of Pharmacy Compounding
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Pharmacy compounding involves the preparation of customized medications that are not commercially available for individual patients with specialized medical needs. Traditional pharmacy compounding is appropriate when done on a small scale by pharmacists who prepare the medication based on an individual prescription. However, the regulatory oversight of pharmacy compounding is significantly less rigorous than that required for Food and Drug Administration (FDA)-approved drugs; as such, compounded drugs may pose additional risks to patients. FDA-approved drugs are made and tested in accordance with good manufacturing practice regulations (GMPs), which are federal statutes that govern the production and testing of pharmaceutical products. In contrast, compounded drugs are exempt from GMPs, and testing to assess product quality is inconsistent. Unlike FDA-approved drugs, pharmacy-compounded products are not clinically evaluated for safety or efficacy. In addition, compounded preparations do not have standard product labeling or prescribing information with instructions for safe use. Compounding pharmacies are not required to report adverse events to the FDA, which is mandatory for manufacturers of FDA-regulated medications. Some pharmacies engage in activities that extend beyond the boundaries of traditional pharmacy compounding, such as large-scale production of compounded medications without individual patient prescriptions, compounding drugs that have not been approved for use in the US, and creating copies of FDA-approved drugs. Compounding drugs in the absence of GMPs increases the potential for preparation errors. When compounding is performed on a large scale, such errors may adversely affect many patients. Published reports of independent testing by the FDA, state agencies, and others consistently show that compounded drugs fail to meet specifications at a considerably higher rate than FDA-approved drugs. Compounded sterile preparations pose the additional risk of microbial contamination to patients. In the last 11 years, three separate meningitis outbreaks have been traced to purportedly 'sterile' steroid injections contaminated with fungus or bacteria, which were made by compounding pharmacies. The most recent 2012 outbreak has resulted in intense scrutiny of pharmacy compounding practices and increased recognition of the need to ensure that compounding is limited to appropriate circumstances. Patients and healthcare practitioners need to be aware that compounded drugs are not the same as generic drugs, which are approved by the FDA. The risk-benefit ratio of using traditionally compounded medicines is favorable for patients who require specialized medications that are not commercially available, as they would otherwise not have access to suitable treatment. However, if an FDA-approved drug is commercially available, the use of an unapproved compounded drug confers additional risk with no commensurate benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Availability of pediatric dose formulations would eliminate concerns about improper compounding of HC from tablets (192)(193)(194).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [193]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Association of Boards of Pharmacy: A New Associate Society of the AAAS
Costello, P. H. (1955) · Science · doi:10.1126/science.121.3144.7a · Cited by 271
Gershman, M., Kennedy, D. J., Noble‐Wang, J., Kim, C., Gullion, J. S., Kacica, M. A., Jensen, B. J., Pascoe, N., Saiman, L. M., McHale, J., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/592968 · Cited by 140 · cited 1×
“There are numerous references regarding adverse events associated with the use of compounded products in the scientific literature [27, 36–48].”
BackgroundNational Association of Boards of Pharmacy
Swain, R. L. (1954) · Journal of the American Pharmaceutical Association (Practical Pharmacy ed ) · doi:10.1016/s0095-9561(16)33466-1 · Cited by 124
Committee Opinion No. 532: Compounded Bioidentical Menopausal Hormone Therapy
(2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318268049e · Cited by 70
Romano, M. J., & Dinh, A. (2001) · PEDIATRICS · doi:10.1542/peds.108.2.471 · Cited by 69
〈797〉 Pharmaceutical Compounding—Sterile Preparations
(2021) · doi:10.31003/uspnf_m99925_06_01 · Cited by 66
Civen, R., Vugia, D. J., Alexander, R., Brunner, W., Taylor, S., Parris, N., Wasserman, R., Abbott, S. L., Werner, S. B., & Rosenberg, J. B. (2006) · Clinical Infectious Diseases · doi:10.1086/507336 · Cited by 61 · cited 1×
“There are numerous references regarding adverse events associated with the use of compounded products in the scientific literature [27, 36–48].”
BackgroundCompounded Colistimethate as Possible Cause of Fatal Acute Respiratory Distress Syndrome
McCoy, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmc071717 · Cited by 60 · cited 1×
“There are numerous references regarding adverse events associated with the use of compounded products in the scientific literature [27, 36–48].”
Background(2004) · GMP/ISO Quality Audit Manual for Healthcare Manufacturers and Their Suppliers, (Volume 2 - Regulations, Standards, and Guidelines) · doi:10.3109/9780203026656-7 · Cited by 54
Research works printed but not linked: 4
- Sterility Tests (general chapter 71). United States Pharmacopeia 35—National Formulary 30. Rockville: United States Pharmacopeial Convention; 2012.
- Institute for Safe Medical Practices Safety Alert. TPN-related deaths call for FDA guidance and pharmacy board oversight of USP chapter 〈797〉. 2011. http://www.ismp.org/newsletters/acutecare/articles/20110407.asp. Accessed July 2012.
- Fricker MP Trissel LA Rich DS Turning a new chapter on IV drug compounding safety: USP/NF chapter 〈797〉 Hosp Pharm 2004 9 899 920
- Kabnick LS. Compounded Sclerosants And Foam: What Should You Know About This Controversial Area? Legal Guidelines for Use of Polidocanol and Sodium Tetradecyl Sulfate for Sclerotherapy. Veith Symposium; 19–23 Nov 2008; New York.
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Nestor, M. S., Ablon, G., Gade, A., Han, H., & Fischer, D. L. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14537 · Cited by 410
Deer, T. R., Pope, J. E., Hayek, S. M., Bux, A., Buchser, E., Eldabe, S., De Andrés, J. A., Erdek, M., Patin, D., Grider, J. S., et al. (2017) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12538 · Cited by 358
Goyanes, A., Madla, C. M., Umerji, A., Duran Piñeiro, G., Giraldez Montero, J. M., Lamas Diaz, M. J., Gonzalez Barcia, M., Taherali, F., Sánchez-Pintos, P., Couce, M.-L., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118497 · Cited by 292
Deer, T. R., Pope, J. E., Hayek, S. M., Lamer, T. J., Veizi, I. E., Erdek, M., Wallace, M. S., Grider, J. S., Levy, R. M., Prager, J., et al. (2017) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12579 · Cited by 174
“In the United States, pharmacy compounding is not regulated by the FDA but rather by state boards of pharmacy, incorporating the United States Pharmacopeia (USP) chapter Pharmaceutical Compounding—nonsterile and sterile preparations (67).”
BackgroundInfluential
Metadata
- Authors
- Gudeman, J., Jozwiakowski, M., Chollet, J., & Randell, M.
- Affiliations
- Northside Hospital (US)
- Corresponding author
- Chollet, John
- ORCID
- Gudeman, Jennifer
- Venue
- Drugs in R&D
- Published
- 2013-03
- Volume
- 13
- Issue
- 1
- Pages
- 1-8
- ISSN
- 1174-5886 (ISSN-L)
- 1179-6901
- PMC
- PMC3627035
- OpenAlex
- W1978751079
- Cited by
- 196
- References
- 30
- Citations by year
- 2026: 8 · 2025: 17 · 2024: 19 · 2023: 12 · 2022: 23 · 2021: 15 · 2020: 18 · 2019: 22 · 2018: 11 · 2017: 19 · 2016: 12 · 2015: 8 · 2014: 9 · 2013: 3
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drugs in R&D (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Keywords
- pharmaceutical compounding, compounded medications, good manufacturing practices, regulatory oversight, product quality testing, adverse event reporting, compounded sterile preparations, microbial contamination, meningitis outbreak, fungal contamination, corticosteroid injection, generic drugs, risk-benefit assessment
- MeSH terms
- Drug Compounding, Pharmaceutical Preparations, Humans, Risk Factors, United States, United States Food and Drug Administration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Risks of Pharmacy Compounding. https://app.cochat.ai/papers/10.1007/s40268-013-0005-9
- The paper
- Gudeman, J., Jozwiakowski, M., Chollet, J., & Randell, M. (2013). Potential Risks of Pharmacy Compounding. Drugs in R&D. https://doi.org/10.1007/s40268-013-0005-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.